NEW ORLEANS — In this video from the American Academy of Ophthalmology meeting, Sunir J. Garg, MD, FACS, FASRS, discusses what has been learned from phase 3 data on two FDA-approved treatments for geographic atrophy. Garg, of Wills Eye Hospital, noted that with pegcetacoplan, patients with nonsubfoveal geographic atrophy responded to treatment better that patients with subfoveal lesions. In addition, over time, both Syfovre (pegcetacoplan injection, Biogen) and Izervay (avacincaptad pegol intravitreal solution, Astellas) showed additive benefit of treatment at 12 months, 18 months and 24

C3 glomerulopathy (C3G) is an uncommon form of complement-mediated glomerular disease marked by dysregulation of the alternative complement pathway, sometimes associated with monoclonal light-chain de...

Extended treatment with pegcetacoplan reduces geographic atrophy progression and preserves retinal tissue over 5 years.

Adolescents with C3G or IC-MPGN achieved a 75% relative reduction in proteinuria on pegcetacoplan versus placebo in the VALIANT subgroup analysis.

Early and continuous pegcetacoplan therapy slows geographic atrophy progression and preserves retinal tissue in AMD.

Geographic atrophy (GA) is the late form of non-exudative (dry) age-related macular degeneration (AMD), and its relentless progression leads to irreversible vision loss.1,2 In 2023, two complement inhibitors were approved by the U.S. Food and Drug Administration (FDA) after both drugs were shown to slow the growth rate of GA.3 Pegcetacoplan 15mg (Syfovre™, Apellis Pharmaceuticals, Waltham, MA) was approved in February 2023, and inhibits complement component 3 (C3) and C3b. The second complement inhibitor, known as avacincaptad pegol 2mg (ACP; Izervay™, Iveric Bio, an Astellas Company, Parsippany, NJ), was approved in August 2023 and inhibits complement C5.

Glossary

In this video, Sunir J. Garg, MD, FACS, FASRS, talked about a post hoc analysis of pegcetacoplan clinical trials in geographic atrophy presented at the American Society of Retina Specialists annual meeting. Garg, chief of the retina service at Wills Eye Hospital and professor of ophthalmology at Thomas Jefferson University, said the results of this analysis of Syfovre (pegcetacoplan injection, Biogen) can help determine which patients would benefit the most from treatment as well as help explain to patients their rate of change before vs. after starting treatment. “I think that would be really

Key PointPegcetacoplan treatment increased Hb levels, reduced hemolysis, and increased FACIT-fatigue scale scores in patients with CAD and wAIHA.